Efficacy of Recombinant Human Endostatin plus Neoadjuvant Chemotherapy for Osteosarcoma and Its Influence on Serum VEGF and MMP-9 Levels

Table 1

Baseline data.

	Control group (n = 65)	Combination group (n = 76)	χ ^2/t
Gender (n (%))			0.0499	0.8231
Male	39 (60.0)	47 (61.8)
Female	26 (40.0)	29 (38.2)
Average age (years)	23.74 ± 2.48	24.05 ± 2.64	0.7146	0.4760
BMI (kg/m^2)	20.97 ± 1.79	21.16 ± 1.94	0.6006	0.5491
Tumor location			0.8834	0.8294
Ulna	12 (18.5)	16 (21.1)
Perone	17 (26.2)	15 (19.7)
Tibia	20 (30.7)	26 (34.2)
Femur	16 (24.6)	19 (25.0)
Pathological type			1.3992	0.4970
Osteoblast	41 (63.1)	55 (72.4)
Chondroblast	14 (21.5)	12 (15.8)
Fibroblast	10 (15.4)	9 (11.8)
Enneking stage			0.7495	0.6875
IIA	10 (15.4)	8 (10.5)
IIB	48 (73.8)	59 (77.6)
III	7 (10.8)	9 (11.9)